Published in Drug Law Weekly, May 12th, 2009
"Primary end point was response rates (RR). All patients were evaluable. The overall RR was 47.5% (95% confidence interval (CI) 32 63). The disease control was 80%. Median time for response was 6 weeks. Median time to progression was 6.3 months (95% CI 5.4-7.2) and the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.